. Author manuscript; available in PMC: 2012 Jun 20.

Published in final edited form as: J Neurooncol. 2011 Nov 27;107(2):269–280. doi: 10.1007/s11060-011-0756-5

Table 3.

CHLA-200, CHLA-259, and CHLA-266 show significant drug resistance compared to DAOY

IC₉₀	4-HC (µg/ml)	CDDP (µg/ml)	ETOP (µg/ml)	VNC (ng/ml)	4-HPR (µM)	L-PAM (µg/ml)	TPT (nM)
CHLA-200	2.6 ± 2.0^*	4.6 ± 0.2^***	2.1 ± 1.0^*	>50^***	6.5 ± 0.2	12.2 ± 5.5^*	>1,000^***
CHLA-259	1.7 ± 0.3	1.8 ± 0.8^*	0.6 ± 0.2^*	1.6 ± 1.4	>12^*	1.3 ± 1	72.2 ± 34.2*
CHLA-266	6.9 ± 3.7^*	2.2 ± 0.5^**	>10^***	>50^***	3.5 ± 0.2	>20^**	>1,000^***
DAOY	1.6 ± 0.3	0.3 ± 0.02	0.15 ± 0.03	2.2 ± 1.0	4.2 ± 1.2	1.7 ± 1.2	3.5 ± 2.0

Shown are IC₉₀ values calculated from experiments performed in Fig. 2. Experiments were performed at least three times and P values were assessed compared to DAOY

4-HC Activated cyclophosphamide, CPPD cisplatin, ETOP etoposide, VINC vincristine, 4-HPR fenretinide, L-PAM melphalan, TPT topotecan P values (compared to DAOY): NS: >0.05;

P < 0.05,

^**

P < 0.01,

^***

P < 0.001